QIAGEN will join the 5th RNA-Seq Summit in San Francisco! This time we are not only showcasing our advanced RNA sequencing bioinformatics solutions, but also presenting our innovative assay technology.
Come and meet our scientists to see how QIAGEN’s RNA sequencing solutions can maximize the value of your research, empowered by Ingenuity Pathway Analysis (IPA) and QIAseq Targeted RNA Panels for gene expression profiling.
We’re also hosting a 4-hour workshop. This workshop will include in-depth coverage of the bioinformatics solutions from QIAGEN used to analyze and interpret whole transcriptome and targeted RNA sequencing results from pre-treatment mRNAs of patients with advanced metastatic melanoma, and with respect to their subsequent immunotherapy treatment outcomes. We will show how to optimize transcriptome data and will provide details on the biological signatures that determine non-responder versus responder status using Ingenuity Pathway Analysis (IPA).
Topic: Understanding innate resistance to anti-PD-1 therapy in melanoma through transcriptomics
Date/time: 9 a.m. – 1 p.m., April 25, 2017
Dr. Jean-Noel Billaud, Senior Principal Scientist – QIAGEN Bioinformatics
Dr. Samuel Rulli, Global Product Manager – QIAGEN
Register now to reserve your spot. Online registration: https://go.qiagen.com/RNAseq2017
We look forward to seeing you in San Francisco from April 25–27!